LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Purchased by Congress Asset Management Co.

Congress Asset Management Co. raised its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 1.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 722,325 shares of the medical instruments supplier’s stock after buying an additional 13,009 shares during the quarter. Congress Asset Management Co. owned approximately 3.21% of LeMaitre Vascular worth $66,555,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. NBC Securities Inc. increased its position in LeMaitre Vascular by 73.2% during the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 183 shares during the last quarter. KBC Group NV grew its stake in shares of LeMaitre Vascular by 58.4% during the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock valued at $102,000 after buying an additional 410 shares during the period. Empowered Funds LLC acquired a new stake in shares of LeMaitre Vascular during the 4th quarter worth $150,000. SG Americas Securities LLC purchased a new position in shares of LeMaitre Vascular in the 4th quarter worth $158,000. Finally, Advisors Asset Management Inc. boosted its holdings in LeMaitre Vascular by 180.2% in the third quarter. Advisors Asset Management Inc. now owns 1,852 shares of the medical instruments supplier’s stock valued at $172,000 after acquiring an additional 1,191 shares during the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Barrington Research upped their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a report on Thursday. They issued an “equal weight” rating and a $95.00 price target on the stock. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Finally, Oppenheimer reissued an “outperform” rating and issued a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $94.63.

LeMaitre Vascular Price Performance

Shares of LMAT stock opened at $98.65 on Friday. The company’s fifty day moving average price is $95.94 and its two-hundred day moving average price is $93.61. The firm has a market capitalization of $2.22 billion, a P/E ratio of 53.91, a P/E/G ratio of 2.19 and a beta of 0.96. LeMaitre Vascular, Inc. has a 12 month low of $59.87 and a 12 month high of $109.58.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.